Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Bone Marrow Transplant • Leukemia • Internal Medicine • Hematology
What is your general approach to post-allogeneic HSCT maintenance therapy for AML?
When is it warranted to utilize targeted therapies for known mutations (eg. midostaurin or an alternative TKI for FLT3 mutations, ivosidenib for IDH1 mutations, enasidenib for IDH2 mutations, etc)?
Is there benefit in patients without targetable mutations with the use of hypomethylating agents such as azacitidine?
Answer from: Medical Oncologist at Academic Institution
Relapse is the most important cause of treatment failure post allo HCT. However, to date no strategy has been conclusively shown to reduce or prevent recurrence.
Having said that we approach every patient with greater than a 30% historical risk of recurrence within 2 years to consider relapse preve...
Thank you for your response! In your experience...